Form 8-K Valeant Pharmaceuticals For: Oct 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Valeant Pharma (VRX) Posts Strong Q3 Results, Bumps Outlook Higher; Aegis Capital Maintains at 'Buy'
October 20, 2014 9:55 AM EDTAegis Capital affirms its Buy rating and $180 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results and guidance update.
Analyst Ram Selvaraju commented, This morning, Valeant reported third quarter 2014 financial results. The firm delivered cash EPS of $2.11 per share vs. our projection of... More
